Ultimate magazine theme for WordPress.
BTC
$8,168.55
-2.06%
ETH
$179.55
-3.16%
LTC
$54.87
-3.24%
DASH
$71.47
-0.45%
XMR
$52.64
-1.18%
NXT
$0.01
ETC
$4.61
DOGE
$0.00
ZEC
$37.10
BTS
$0.03
DGB
$0.01
-5.77%
XRP
$0.29
-2.09%
BTCD
$20.52
PPC
$0.28
-3.96%
CRAIG
$0.00
XBS
$0.02
0%
XPY
$0.04
0%
PRC
$0.01
0%
YBC
$22.87
0%
DANK
$0.00

Stocks to Watch: Advanced Emissions Solutions, Inc. (NASDAQ:ADES), Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB)

67

Advanced Emissions SolutionsAdvanced Emissions Solutions, Inc. (NASDAQ:ADES) update; CCS JV finalizes contract with new Refined Coal investor; Leased and sold RC facilities expected to generate more than $100 million in annual revenues to CCS. Advanced Emissions Solutions, Inc. (NASDAQ:ADES) announced Clean Coal Solutions, LLC, a joint venture among its subsidiary ADA-ES, an affiliate of NexGen Resources Corporation, and an affiliate of The Goldman Sachs Group, Inc., has transferred the membership interests of a special purpose entity holding a Refined Coal facility in exchange for fixed and variable payments that provide to CCS similar economics to those of its other leased and sold RC facilities in full-time operation. The limited liability company is 49.9% owned by a new RC investor with certain CCS affiliates, including an affiliate of the co, holding the remaining equity.

Advanced Emissions Solutions, Inc. (NASDAQ:ADES) shares fell -0.85% to $55.08 in current session.

Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) announces priority review for the sNDA to expand lymphoseek labeling for sentinel lymph node detection in patients with head and neck cancer. Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) has announced that the U.S. Food and Drug Administration (:FDA) has accepted the Supplemental New Drug Application (sNDA) and granted a Priority Review for the expanded use of Lymphoseek (technetium 99m tilmanocept) Injection indicated for sentinel lymph node (:SLN) detection in patients with head and neck cancer. Under the Prescription Drug User Fee Act (:PDUFA), the FDA has set a target review date for the Lymphoseek sNDA of June 16, 2014.

The FDA grants priority review status to drug applications that may offer a significant improvement in treatment over existing options. Lymphoseek is currently approved for use in lymphatic mapping procedures performed to aid in the diagnostic evaluation of lymph nodes draining a primary tumor in patients with breast cancer and melanoma.

Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) share fell -0.52% to $1.93 in current session.

Comments